AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NEW ORLEANS -- The overall risk of cardiovascular events is extremely low in healthy women in early menopause who rely on hormone therapy to treat their menopausal symptoms, according to pooled data from four large randomized clinical trials.
These findings contrast with those from other recent trials showing increased risk of coronary disease in the first year of hormone replacement therapy (HRT) in women using certain regimens. The new findings suggest that those from the widely publicized Women's Health Initiative (V/HI) study and the Heart and Estrogen/Progestin Replacement Study (HERS), for example, do not apply to younger postmenopausal women taking hormones for treatment of menopausal symptoms, Dr. Rogerio Lobo reported in a poster session at the annual meeting of the American College of Obstetricians and Gynecologists.
The average age of patients in the WHI was 67 years, and that in HERS was 63 years. Women in those studies were not using hormones for the treatment of menopausal symptoms. The average age of patients in the current study was 53 years, said Dr. Lobo of Columbia-Presbyterian Medical Center, New York.
In the WHI, the hazard ratio for cardiovascular events in women aged 50-59 was 1.67. The annual event rate, based on first-year findings, would be 2.23 per 1,000 HRT users--a markedly higher rate than the 0.17 events per 1,000 patient years noted in the current study.
The data used in Dr. Lobo's study came from the Women's Health, Osteoporosis, Progestin, Estrogen study (Fertil. Steril. 75:1065-79, 2001), the Menopause Study Group (Obstet. Gynecol. 83[5 pt. 1]:686-92, 1994), and two studies on file at Wyeth Research (Philadelphia), which sponsored Dr. Lobo's study.
Various hormonal regimens were used in these studies, including conjugated equine estrogen (CEE) alone, CEE plus medroxyprogesterone acetate, CEE with trimegestone, estradiol-17[beta] with trimegestone, and estradiol-17[beta] with ...
Source: HighBeam Research, Cardiac event risk low in young, healthy HRT users: WHI findings may...